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Abstract
Background—Prognosis and survival are significant concerns for individuals with heart failure
(HF). In order to better understand the pathophysiology of HF prognosis, the association between
2,366,858 single nucleotide polymorphisms (SNPs) and all-cause mortality was evaluated among
individuals with incident HF from four community-based prospective cohorts: the Atherosclerosis
Risk in Communities Study, the Cardiovascular Health Study, the Framingham Heart Study, and
the Rotterdam Study.
Methods and Results—Participants were 2,526 individuals of European ancestry and 466
individuals of African ancestry who suffered an incident HF event during follow-up in the
respective cohorts. Within each study, the association between genetic variants and time to
mortality among individuals with HF was assessed by Cox proportional hazards models that
included adjustment for sex and age at the time of the HF event. Prospective fixed-effect meta-
analyses were conducted for the four study populations of European ancestry (N=1,645 deaths)
and for the two populations of African ancestry (N=281 deaths). Genome-wide significance was
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set at P=5.0×10-7. Meta-analytic findings among individuals of European ancestry revealed one
genome-wide significant locus on chromosome 3p22 in an intron of CKLF-like MARVEL
transmembrane domain containing 7 (CMTM7, p = 3.2×10-7). Eight additional loci in individuals
of European ancestry and four loci in individuals of African ancestry were identified by high-
signal SNPs (p < 1.0×10-5), but did not meet genome-wide significance.
Conclusions—This study identified a novel locus associated with all-cause mortality among
individuals of European ancestry with HF. This finding warrants additional investigation,
including replication, in other studies of HF.
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Introduction
Heart failure (HF) is a relatively common chronic condition characterized by the inability of
the heart to efficiently pump blood and represents a significant public health burden,
affecting nearly 6 million Americans. Prognosis and survival are a significant concern: after
HF is diagnosed, 1 in 5 die within one year1, often by sudden cardiac death which occurs 6
to 9 times more often than in the general population.1,2
The public health burden of HF and its associated mortality is likely to intensify due to the
aging population and an increase in the prevalence of HF risk factors, such as coronary
artery disease, obesity and diabetes. The Cohorts for Heart and Aging Research in Genome
Epidemiology (CHARGE) consortium includes the Atherosclerosis Risk in Communities
(ARIC) Study, the Cardiovascular Health Study (CHS), the Framingham Heart Study (FHS),
the Rotterdam Study (RS) and the National Institute of Aging's Iceland Age, Gene/
Environment Susceptibility (AGES) Study.3 The CHARGE consortium provided an
opportunity to evaluate genetic factors associated with the prognosis of HF, and the
association between genome-wide variation and all-cause mortality was investigated among
2,526 incident HF cases of European ancestry and 466 incident HF cases of African
ancestry. 4
Methods
Design and Study Population
The design for this study is a cohort of individuals with incident HF nested within four of
the population-based studies (ARIC, CHS, FHS and RS) of the CHARGE consortium. A
detailed description of each cohort study design has been published elsewhere.5-9 Selection
of eligible incident HF cases (with available genome-wide scan data) and methodology for
genotyping and genotype imputation are published.4 HF cases were identified during
1987-2004 for ARIC, 1989-2007 for CHS, 1988-2006 for FHS and 1990-2006 for RS.
Details regarding HF diagnostic criteria are shown in supplemental Table S1.
Briefly, eligible participants for these analyses were individuals of European or African
ancestry who suffered an incident HF event during follow-up and had genome-wide
association data. Identification of incident HF events relied on multiple sources of clinical
and administrative data. The approach was similar across the four studies and is described in
more detail in previously published reports.4,10,11 A total of 2,526 incident HF events were
identified from 20,926 participants of European ancestry from all four cohorts over a
weighted average of 11.5 years of follow-up.4 A total of 466 HF events were identified over
an average of 13.7 years among 2,895 individuals of African ancestry from ARIC and CHS.
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4 Each study received IRB approval and all participants provided written informed consent
for the use of their DNA for research.
Genotyping and Imputation
For the individuals of European ancestry, each study independently imputed their genotype
data to approximately 2.4 million autosomal single nucleotide polymorphisms (SNPs)
identified in HapMap CEU samples. Imputed genotypes were not determined in ARIC
individuals of African ancestry and genotypes available for analysis were restricted to
successfully genotyped SNPs on the Affymetrix 6.0 chip. In CHS individuals of African
ancestry, SNP data were imputed using information from HapMap YRI and CEU samples
and were then restricted to the same set of SNPs evaluated in ARIC individuals of African
ancestry. Imputation results were summarized as an “allele dosage” defined as the expected
number of copies of the minor allele at that SNP (a fractional value between 0.0 and 2.0). A
ratio of observed versus expected variance (OEV) of the dosage for each SNP was
calculated within each cohort as a measure of imputation quality.
Characteristics of Participants with HF
For these analyses, measures of clinical and demographic characteristics were obtained from
the clinical visit preceding HF onset. At in-person visits, clinical measures were collected
(annually in CHS from 1989 through 1999, biennially in the original cohort and
approximately every four years in the offspring cohort of FHS, every three years in ARIC
through 1998, and every three years in RS). Measures were taken using standardized
methods as specified by each study and included in-person measures of height, weight,
systolic and diastolic blood pressure, and total cholesterol. Each study also identified
individuals with hypertension, diabetes or myocardial infarction that occurred prior to HF
diagnosis.
Mortality Ascertainment
Participants were followed prospectively with in-person visits and telephone contacts in
most cohorts. Deaths were defined as all-cause mortality. In the ARIC study, deaths were
ascertained through annual phone calls or through ongoing surveillance of health department
death certificate files through December 31, 2004. In CHS, participant mortality was
identified at 6-month surveillance contacts, National Death Index searches, and from
obituaries through June 30, 2007. Additional information about cause of death was collected
from death certificates, proxy interviews, and medical records.11 In the RS, deaths were
ascertained through general practitioner medical records and from municipal records
through January 1, 2007. All FHS participants are under continuous surveillance based on
periodic Heart Study visits and biannual health history updates. Information on death (and
cause of death) is obtained from hospitalization records, medical records, death certificate,
family members and obituaries. All deaths are reviewed by an endpoints adjudication panel
consisting of three FHS physicians. The mortality ascertainment rate for each cohort is
greater than 99%.
Statistical Analyses
The association between genomic variation and time to death among individuals with
incident HF was evaluated separately in each cohort by Cox proportional hazards models.
The follow-up time interval was defined as the time between the date of incident HF and the
date of death, last contact if lost to follow-up, or the end of follow-up, whichever came first.
Each model was evaluated separately in individuals with HF of European or African
ancestry, and included adjustment for sex and age at the time of the HF event. In addition,
CHS adjusted for study site and FHS adjusted for generation and ancestry using principal
Morrison et al. Page 3













components.12 ARIC and RS did not include additional adjustments in the analysis model.
All SNPs were evaluated for association under an additive genetic model.
Across the four study populations of European ancestry and separately the two populations
of African ancestry, fixed-effect meta-analyses combined β-coefficients and study-specific
p-values using genomic control lambdas to adjust for remaining population substructure.
The meta-analysis produced an overall hazards ratio (HR), standard error and a p-value.
Prior to meta-analysis, a filter was applied to SNPs with a β-coefficient greater than 5.0 or
less than -5.0 to avoid numerical instabilities. Meta-analyses were performed using
MetABEL software (http://mga.bionet.nsc.ru/∼yurii/ABEL/)13 and METAL
(http://www.sph.umich.edu/csg/abecasis/Metal/index.html) for confirmation. To avoid
inaccuracies in the asymptotic assumptions of Cox models when the number of events
carrying the variant allele was small (i.e., <70 individuals with an endpoint and carrying the
minor allele), SNPs were excluded from further consideration when the post-meta-analysis
population-size-weighted minor allele frequency (MAF) was ≤0.03 in individuals of
European ancestry and ≤0.135 in individuals of African ancestry.
For each ancestry group, a quantile-quantile (Q-Q) plot was generated from Cox
proportional hazards models and shows the distribution of the observed and expected p-
values for all SNPs. Also, meta-analyzed p-values were plotted according to location across
the 22 autosomes. An a priori threshold of 5.0×10-7 was used to indicate genome-wide
significance in the analysis of individuals of European and African ancestry.14 High-signal
SNPs had a p-value smaller than 1.0×10-5, but did not meet genome-wide significance. If
more than one significant or high-signal SNP clustered at a locus, the SNP with the smallest
p-value was reported as the locus marker. Regional plots showing detailed linkage
disequilibrium (LD) and gene location information and forest plots were created for
genome-wide significant markers. Additionally, top hits from the meta-analysis in the
European and African ancestry populations were compared. The minor allele frequencies,
hazard ratios and p-values for these markers are reported for each ancestral population.
Results
Among the 2,526 participants of European ancestry with incident HF, a total of 1,645 deaths
from all causes occurred at a weighted average of 3.6 years. A total of 281 deaths occurred
among the 466 individuals with incident HF of African ancestry at a weighted average of 3.4
years. Baseline characteristics of cohort participants with incident HF are shown in Table 1.
The weighted average age at diagnosis of HF was 77.3 years (range from 44 to 101) among
individuals of European ancestry and 70.0 years (range from 46 to 96) among individuals of
African ancestry.
Participants of European Ancestry
Figure 1 shows the Q-Q plot of p-values derived from the approximately 2.4 million tests
performed in participants of European ancestry plotted against the expected distribution.
Except for some of the very lowest p-values, the observed and expected distributions of p-
values were similar. The genomic inflation lambda values for the individual cohorts were
0.95 for CHS, 0.99 for RS, 1.00 for ARIC and 1.09 for FHS. The meta-analysis genomic
inflation lambda value for those of European ancestry was equal to 1.0, suggesting minimal
population stratification or other technical artifacts. Figure 2 presents p-values for the
approximately 2.4 million SNPs organized by chromosome and genomic position. As shown
in Table 2, one SNP (rs12638540, p-value = 3.21×10-7, HR=1.53, genome-wide confidence
interval 1.01-2.31, MAF of 0.04) on chromosome 3p22 exceeded the pre-specified genome-
wide significance threshold. This SNP resides in an intron of CKLF-like MARVEL
transmembrane domain containing 7 (CMTM7), and was genotyped in RS and FHS and
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imputed with high quality in ARIC (OEV=0.981) and CHS (OEV=0.921). Figure 3 presents
detailed information about LD structure and p-values for other SNPs in this region, and a
forest plot of the meta-analysis findings is shown in Figure 4.
In addition to the one SNP exceeding genome-wide significance, fourteen additional high-
signal SNPs were identified with p-values less than 1.0×10-5 that marked eight chromosomal
regions of interest. Table 2 provides detail about those loci identified in individuals of
European ancestry. Of these eight loci, the OTU domain containing 7A (OTUD7A),
glycoprotein M6A (GPM6A), alpha parvin (PARVA) and interferon-related developmental
regulator 1 (IFRD1) genes were identified by a single intronic SNP. An intergenic SNP on
chromosome 19 was 34.6 kb from the latrophilin 1 (LPHN1) gene. An intergenic SNP on
chromosome 10 was 46.6 kb from the potassium large conductance calcium-activated
channel, subfamily M, alpha member 1 (KCNMA1) gene, and an intergenic SNP on
chromosome 5 was 77.6 kb from the solute carrier family 25, member 46 (SLC25A46) gene.
An intergenic region on chromosome 12 was also identified. Cohort-specific results for the
index markers for each locus are provided in supplemental Table S2.
Participants of African Ancestry
Figure 5 shows the Q-Q plot of p-values derived from the 560,383 tests performed in
participants of African ancestry. Except for some of the very lowest p-values, the observed
and expected distributions of p-values were similar. Figure 6 presents all p-values organized
by chromosome and genomic position. In individuals of African ancestry with incident HF,
no SNP exceeded the pre-specified genome-wide significance threshold for an association
with mortality. Five high-signal SNPs were identified with p-values less than 1.0×10-5 that
marked four loci of interest (Table 2). The smallest p-value among individuals of African
ancestry was for an intronic SNP in the ADAM metallopeptidase with thrombospondin type
1 motif, 12 (ADAMTS12) gene. Two SNPs were within 27.7 kb from the potassium channel,
subfamily K, member 13 (KCNK13) gene and one SNP was in the promoter region of F-box
protein 34 (FBXO34). An additional intergenic SNP was greater than 100 kb from a known
gene on chromosome 1. Cohort-specific results are provided in supplemental Table S2.
Cross Ancestry Comparisons
None of the loci identified in the African ancestry analysis were associated with mortality in
individuals with HF of European ancestry (all p-values > 0.05). The genome-wide
significant and high-signal SNPs among individuals of European ancestry were not
associated with mortality among African ancestry CHS participants (all p-values >0.05).
These SNPs were only imputed and evaluated for an association in CHS participants of
African ancestry and were not imputed in individuals of African ancestry from the ARIC
study. The minor allele frequency for rs12638540 is 0.07 in CHS individuals with heart
failure of African ancestry.
Discussion
This study evaluated the association between genome-wide genetic variation and all-cause
mortality among individuals with incident HF. The meta-analysis included 2,526 individuals
of European ancestry with HF and revealed an intronic SNP in CMTM7 on chromosome 3
that exceeded genome-wide significance and was associated with a 53% increase in risk of
death. Approximately 8% of the HF population carried this variant. Among African ancestry
participants, no SNP had a p-value that exceeded genome-wide significance. Additional
high-signal SNPs identified in either the European or African ancestry populations were in
or close to LPHN1, OTUD7A, GPM6A, PARVA, KCNMA1, IFRD1, SLC25A46,
ADAMTS12, KCNK13 and FBXO34 (p-value range between 1.10×10-6 and 9.64×10-6).
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Regions of the genome without known genes also identified in these analyses reside on
chromosome 1q41 and 12q24. SNPs identified in GWAS for incident heart failure4 did not
overlap with those identified here.
The genome-wide significant association was for CMTM7, one of several chemokine-like
factor genes clustered in the same region on chromosome 3p22. The protein encoded by
CMTM7 is highly expressed in leukocytes and is also expressed in the heart, but its function
is unknown. A recent study indicates that chemokine receptor gene expression is
upregulated among HF patients compared with controls.15 The CMTM7 chemokine-like
factor may act as a chemoattractant to guide migration of cells in the heart. Some
chemokines play a role as a pro-inflammatory marker in the context of an immune response
or may promote angiogenesis during HF.
Of the 12 loci that did not meet genome-wide significance, four merit further discussion.
The observed association with OTUD7A in individuals of European ancestry, and the
association with FBXO34 in individuals of African ancestry, suggests that these genes may
play a role in HF progression and survival by contributing to inadequate degradation of
ubiquitin/protein conjugates and resulting in autophagic myocyte death. A mouse model for
desmin-related cardiomyopathy indicates that accumulation of polyubiquitinated proteins is
correlated with hastened HF progression.16 Other studies show that ubiquitinated proteins
accumulate in the cytosol of human hearts with idiopathic or ischemic cardiomyopathies.
17,18 The observed association with potassium channels encoded by KCNMA1 in individuals
of European ancestry and KCNK13 in individuals of African ancestry provides evidence that
control of vascular tone and regulation of the contraction of cardiac smooth muscle may be
important components of HF progression and survival. Substantial previous work has
documented that potassium channels are associated with cardiovascular and mortality
endpoints.19-24
Although there was not a consistent finding for a particular SNP across the European and
African ancestry populations, genes involved in deubiquitinating activity and genes
encoding potassium channels were identified in each ethnic group. It is important to note
that for many loci, there was a clear difference in the MAF between ethnic groups. This
difference in MAF coupled with variable patterns of LD between the populations obfuscates
the interpretability of cross-ancestral comparisons. In addition, it is known that certain HF
treatments affect length of survival with HF, and access to care and treatment practices are
known to vary by region and ethnicity.25,26
Study Strengths and Limitations
Although this is the largest study to date of individuals with incident HF evaluated for an
association between genome-wide genetic variation and all-cause mortality, there are study
limitations. SNP imputation in individuals of European ancestry resulted in the ability to
meta-analyze results across approximately 2.4 million SNPs. Given 2.4 million tests, one
significant SNP is what would have been expected by chance for the a priori level of
genome-wide significance and only one SNP exceeded this threshold in individuals of
European ancestry. This finding may represent a false positive result and requires replication
in other studies. Similarly, the number of high-signal loci identified in either ancestry group
was far fewer than would be expected by chance given a threshold of P=1.0×10-5.
For some variants, imputation quality varied and there was reduced statistical power to
detect an association for poorly imputed SNPs. Across-ancestry comparisons were limited to
data from CHS individuals of African ancestry, and the overall statistical power to detect an
association was limited in African ancestry participants given a total sample of 466
individuals.
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Due to limited data availability across the cohorts, this study did not account for ejection
fraction, treatment for heart failure, socioeconomic status, access to medical care or
hospitalizations subsequent to HF diagnosis. Heterogeneity among the individuals
investigated for this study may have resulted from variation in heart failure diagnostic
criteria across the four studies. However, a study comparing diagnostic criteria between
CHS and FHS showed that all-cause mortality rates were similar across these diagnostic
classifications.27 A study evaluating heart failure diagnosis by central adjudication
compared to hospital discharge diagnoses showed that mortality rates are similar.28 A
limitation of this study is that given differences in diagnostic criteria, the heart failure cases
may not represent the same disease. Since the four study populations likely comprise both
systolic and diastolic heart failure, it is important to note that the cause of death may be
markedly different between these two disease states. This study addressed all-cause
mortality and there was lack of information across cohorts to adequately conduct analyses of
cause-specific mortality.
Finally, the observed signals are described in the context of the nearest gene; however, it is
possible that true causal variants may be in neighboring genes or intergenic regions.
Additional signals may have been missed due to coverage in particular genomic regions or
the lack of statistical power to detect modest effects.
Conclusions
This study investigated 2,526 incident HF cases of European ancestry from ARIC, CHS,
FHS and RS and 466 incident HF cases of African ancestry from ARIC and CHS for an
association between genome-wide variation and all-cause mortality. One SNP in CMTM7
was significantly associated with all-cause mortality in individuals of European ancestry
with HF, suggesting a role of chemokines with survival. However, no SNP was found to be
significantly associated with mortality in individuals with HF of African ancestry. Future
studies of this type, especially those that address some of the limitations of this study, may
identify genes that lead to an improved understanding of HF pathophysiology and treatment
of the disease. These findings warrant additional investigation, including replication, in
other studies of HF.
This study investigated 2,526 incident heart failure cases of European ancestry and 466
incident heart failure cases of African ancestry for an association between genome-wide
variation and all-cause mortality. One variant in the CKLF-like MARVEL
transmembrane domain containing 7 (CMTM7) genes was significantly associated with
all-cause mortality in individuals of European ancestry with heart failure. CMTM7 is one
of several chemokine-like factor genes clustered in the same region on chromosome
3p22. These results suggest that chemokines may play a role in survival of heart failure
patients. No genomic variation was significantly associated with mortality in individuals
with heart failure of African ancestry. Future studies of this type may identify genes that
lead to an improved understanding of heart failure pathophysiology and treatment of the
disease. These findings warrant additional investigation, including replication, in other
studies of heart failure.
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Plot of the expected and observed -log P-values from analyses of participants of European
ancestry.
Morrison et al. Page 11














Among participants of European ancestry, the -log P-value of the additive genetic model for
each SNP with a study size-weighted average minor allele frequency of greater than or equal
to 3%, according to location in the 22 autosomal chromosomes. Horizontal line indicates the
5.0×10-7 threshold of genome-wide significance.
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Regional association plot for the genome-wide significant marker, rs12638540, in
individuals of European ancestry. The top marker is presented in black font and neighboring
variants are presented in different colors based on linkage disequilibrium: yellow: r2 ≥ 0.2
and < 0.5; and white: r2 < 0.2. There were no SNPs in the area with LD ≥ 0.5 with the top
marker.
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Meta-analysis and study-specific hazards ratios and confidence intervals (α=5.0×10-7) for
rs12638540 associated with all-cause mortality in individuals of European ancestry.
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Plot of the expected and observed -log P-values from analyses of participants of African
ancestry.
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Among participants of African ancestry, the -log P-value of the additive genetic model for
each SNP with a study size-weighted average minor allele frequency of greater than or equal
to 13.5%, according to location in the 22 autosomal chromosomes. Horizontal line indicates
the 5.0×10-7 threshold of genome-wide significance.
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